• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Entera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    5/9/25 4:05:25 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENTX alert in real time by email
    false000163809700-00000009722-532-7151Warrants, each Warrant exercisable for half of an Ordinary Share at an exercise price of $5.85 per Ordinary ShareENTXWNASDAQNASDAQ00016380972025-05-092025-05-090001638097entx:OrdinarySharesParValueOfNIS00000769Member2025-05-092025-05-090001638097entx:WarrantsEachWarrantExercisableForHalfOfAnOrdinaryShareAtAnExercisePriceOf585PerOrdinaryShareMember2025-05-092025-05-09
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 9, 2025
     
    Entera Bio Ltd.
    (Exact Name of Registrant as Specified in Its Charter)
     
    Israel
     
    001-38556
     
    Not Applicable
    (State or other jurisdiction
    of incorporation)
     
    (Commission File Number)
     
    (I.R.S. Employer
    Identification)
     
    KIRYAT HADASSAH, MINRAV BUILDING – FIFTH FLOOR, JERUSALEM, Israel 9112002
    (Address of principal executive offices) (Zip Code)

    +972-2-532-7151
    (Registrant’s Telephone Number, Including Area Code)
      
     
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Ordinary Shares, par value of NIS 0.0000769
     
    ENTX
     
    Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     

     
    Item 2.02 Results of Operations and Financial Condition.
     
    On May 9, 2025, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
     
    Item 7.01 Regulation FD Disclosure.
     
    The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
     
    The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits.

    Exhibit
    Number
     
    Description
    99.1

    Press Release dated May 9, 2025 announcing the Company’s financial results and business updates for the three months ended March 31, 2025.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

       
    ENTERA BIO LTD.
         
    Date: May 9, 2025
    By:
    /s/ Miranda Toledano
       
    Name: Miranda Toledano
    Title: Chief Executive Officer


    Get the next $ENTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Gautam Leslie Velka

      3 - Entera Bio Ltd. (0001638097) (Issuer)

      5/20/25 4:30:18 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Galitzer Hillel was granted 26,316 units of Ordinary Shares, increasing direct ownership by 41% to 90,573 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/30/25 4:22:04 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Lieberman Gerald M exercised 23,952 units of Ordinary Shares at a strike of $1.00, increasing direct ownership by 9% to 300,160 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      4/3/25 4:06:27 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Entera Bio with a new price target

      B. Riley Securities initiated coverage of Entera Bio with a rating of Buy and set a new price target of $9.00

      6/16/21 6:22:06 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aegis Capital initiated coverage on Entera Bio with a new price target

      Aegis Capital initiated coverage of Entera Bio with a rating of Buy and set a new price target of $12.00

      3/22/21 10:40:44 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Maxim Group reiterated coverage on Entera Bio with a new price target

      Maxim Group reiterated coverage of Entera Bio with a rating of Buy and set a new price target of $10.00 from $5.00 previously

      3/11/21 12:09:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

      JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture. The Phase 2 study randomized 161 postmenopausal women

      6/26/25 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

      MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment and as a weekly subcutaneous injection for patients with

      6/25/25 8:00:00 AM ET
      $ENTX
      $OPK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taitel Haya bought $9,405 worth of Ordinary Shares (9,500 units at $0.99), increasing direct ownership by 37% to 35,115 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/16/24 8:00:12 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taitel Haya bought $5,864 worth of Ordinary Shares (7,615 units at $0.77), increasing direct ownership by 42% to 25,615 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      1/11/24 6:14:57 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lieberman Gerald M bought $17,006 worth of Ordinary Shares (23,952 units at $0.71), increasing direct ownership by 12% to 226,961 units (SEC Form 4)

      4 - Entera Bio Ltd. (0001638097) (Issuer)

      12/27/23 5:00:37 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by Entera Bio Ltd.

      EFFECT - Entera Bio Ltd. (0001638097) (Filer)

      6/9/25 12:15:24 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Entera Bio Ltd.

      424B3 - Entera Bio Ltd. (0001638097) (Filer)

      6/6/25 4:08:47 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Entera Bio Ltd.

      DEFA14A - Entera Bio Ltd. (0001638097) (Filer)

      6/5/25 4:28:12 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      11/20/24 1:48:55 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      8/20/24 6:01:17 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Entera Bio Ltd. (Amendment)

      SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

      1/16/24 10:45:49 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

      JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. "During Q1 2025, Entera continued to generate intrinsic value with progress across our programs while significantly extending our cash runway into late 2026 via direct investment from marquis investors and our strategic partner, OPKO Health Inc. ("OPKO"). EB613 early mechanistic effects on both trabecular and cortical bone compartments data using 3D-Shaper software analysis was selected for oral presentation out of 1,680 abstracts submit

      5/9/25 4:05:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

      JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company"), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings more than 20 years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle mana

      5/15/24 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

      JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced that it has appointed Haya Taitel, Head of Sanofi's Global Transplant Franchise as an independent director to the Company's Board of Directors. "We are thrilled that Haya has joined our Board," said Miranda Toledano, Chief Executive Officer of Entera. "With more than 30 years of experience building industry-leading commercial organizations across big pharma and biotech, Haya brings a veteran and unique perspective to Entera's Board of Directors. We believe that Haya's track record shepherd

      6/7/23 7:30:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENTX
    Financials

    Live finance-specific insights

    See more
    • Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

      JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World's First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA)

      11/10/22 4:15:00 PM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

      Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT  BOSTON and JERUSALEM, May 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its financial and operating results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Highlights EB613 Clinical Update: Entera's lead clinical candidate, EB613, an oral formulation of human parathyroid hormone (1-34), o

      5/12/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio to Report First Quarter 2022 Financial Results on May 12

      BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday, May 12, 2022 at 8:30 AM EDT. Thursday, May 12, 2022, 8:30 AM EDTDomestic: 877-269-7756International: 201-689-7817Israel: 1809406247Conference ID: 13728252 Webcast: Entera Bio Earnings Webcast A replay of the webcast will be archived on Entera's website for approximately 45 days following the call. About Entera BioEntera is a leader in the development of orally delivered large molecule therapeutics for use in a

      4/28/22 8:00:00 AM ET
      $ENTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care